EyePACS, LLC

EyePACS, LLC is a US-based healthcare technology company focused on preventing diabetic blindness through early detection and management of diabetic retinopathy via an integrated retinal screening platform. Founded in 2010 and headquartered in Santa Cruz, California, EyePACS, LLC specializes in retinal screening solutions for primary care settings. The company has established partnerships with various healthcare providers and public health agencies across the United States. In November 2025, Optain Health Pty Ltd, a portfolio company of Lumio Capital, Informed Ventures, Meridian Ventures, Memorial Hermann Health System Foundation, UPMC Health System, Novant Health, Insight Partners, Aegis Ventures and Northwell Holdings, acquired EyePACS, LLC.

EyePACS offers an integrated platform designed to facilitate the prevention of diabetic blindness through early detection and management of diabetic retinopathy (DR). Their core services include retinal screening conducted in primary care settings, significantly increasing the likelihood that diabetic individuals receive timely retinal exams. Their customer base includes healthcare providers, clinics, and public health agencies in the United States, with partnerships enhancing their platform's credibility and reach. EyePACS generates revenue through partnerships with healthcare providers and clinics that implement their retinal screening services.

These partnerships typically involve contractual agreements where clinics subscribe to utilize the EyePACS platform, often involving a fee structure based on the number of screenings performed or a flat subscription fee for technology access and support services. This model emphasizes long-term collaboration, ensuring financial sustainability for partnering organizations while enhancing patient care. In the upcoming period, EyePACS will leverage its recent acquisition by Optain to enhance its retinal screening capabilities in primary care. The integration aims to improve access to EyePACS' technology.

This strategic move aligns with the company's plan to expand its reach within primary care networks, allowing for increased adoption of their screening services. The acquisition is expected to support these initiatives by streamlining operations and enhancing service delivery.